Brian Druker
Director/Board Member bij AMGEN INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Brian J.
Druker is the founder of MolecularMD Corp.
(founded in 2005) and Blueprint Medicines Corp.
(founded in 2008).
He currently holds multiple positions, including Independent Director at Amgen, Inc. since 2018, Director & Associate Dean at Oregon Health & Science University since 2010, Director at The Burroughs Wellcome Fund, Independent Director at Vincerx Pharma, Inc. since 2020, and Director at OHSU Knight Cancer Institute since 2007.
Dr. Druker's education includes undergraduate and doctorate degrees from the University of California San Diego.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
AMGEN INC.
0.00% | 19-05-2023 | 5 688 ( 0.00% ) | 2 M $ | 31-03-2024 |
VINCERX PHARMA INC
0.26% | 25-05-2023 | 54 806 ( 0.26% ) | 277 318 $ | 31-03-2024 |
Actieve functies van Brian Druker
| Bedrijven | Functie | Begin |
|---|---|---|
| AMGEN INC. | Director/Board Member | 23-05-2018 |
| VINCERX PHARMA, INC. | Director/Board Member | 23-12-2020 |
| Oregon Health & Science University | Director/Board Member | 01-07-2007 |
The Burroughs Wellcome Fund
 The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Director/Board Member | - |
| OHSU Knight Cancer Institute | Director/Board Member | 01-07-2007 |
Eerdere bekende functies van Brian Druker
| Bedrijven | Functie | Einde |
|---|---|---|
MolecularMD Corp.
 MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | Founder | - |
| BLUEPRINT MEDICINES CORPORATION | Founder | - |
Opleiding van Brian Druker
| University of California San Diego | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Miscellaneous |
MolecularMD Corp.
MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | Health Services |
| Vincerx Pharma, Inc. | |
| OHSU Knight Cancer Institute |
